Search
ciltacabtagene autoleucel (Carvykti)
Indications:
- treatment of adult patients with relapsed or refractory multiple myeloma after >= prior lines of therapy, including:
- a proteasome inhibitor
- an immunomodulatory agent
- an anti-CD38 monoclonal antibody.
* for autologous use only
Dosage:
- administer a lymphodepleting regimen of cyclophosphamide & fludarabine before infusion
- do NOT use a leukodepleting filter
- premedicate with acetaminophen & an H1-antihistamine
- confirm availability of tocilizumab prior to infusion
- 0.5-1.0 x 10E6 CAR-positive viable T-cells/kg
- maximum: 1 X 10E8 CAR-positive viable T-cells per infusion
Adverse effects:
- cytokine release syndrome
- prolonged & recurrent cytopenias
- hypogammaglobulinemia
Mechanism of action:
- B-cell maturation antigen-directed genetically modified autologous T-cell immunotherapy
General
chimeric antigen-receptor (CAR) T-cell therapy; tisagenlecleucel; CTL019 (Kymriah)
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Carvykti (ciltacabtagene autoleucel) suspension for intravenous infusion
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf